Funding has been flowing into biotech over the past few years.
Over one week earlier this year, biotech and healthcare startups raised almost $1 billion in capital. And on Tuesday, a cancer-drug startup called Allogene raised $300 million in its series A round.
All the funding has led to a lot of unicorns, as companies with multibillion-dollar valuations have raised hundreds of millions, predominantly during their series A or B rounds.
Image: Reuters
